<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01769235</url>
  </required_header>
  <id_info>
    <org_study_id>CLBG 1210</org_study_id>
    <nct_id>NCT01769235</nct_id>
  </id_info>
  <brief_title>Study Comparing Clindamycin Phosphate and Benzoyl Peroxide Gel to Acanya® Gel and Both to a Vehicle Control in the Treatment of Acne Vulgaris</brief_title>
  <official_title>A Multicenter, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Study Comparing Taro Pharmaceutical Inc.'s Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5% to the Reference Listed Acanya® (Clindamycin Phosphate and Benzoyl Peroxide)Gel, 1.2%/2.5% and Both Active Treatments to a Vehicle Control in the Treatment of Acne Vulgaris</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Taro Pharmaceuticals USA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Taro Pharmaceuticals USA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to compare the safety and efficacy profiles of Taro&#xD;
      Pharmaceutical Inc.'s Clindamycin Phosphate and Benzoyl Peroxide Gel 1.2%/2.5% to Acanya®&#xD;
      (Clindamycin Phosphate and Benzoyl Peroxide) Gel, 1.2%/2.5% and to demonstrate the superior&#xD;
      efficacy of the two active formulations over that of the vehicle in the treatment of acne&#xD;
      vulgaris.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2012</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">September 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean percent change in inflammatory lesion counts.</measure>
    <time_frame>12 weeks</time_frame>
    <description>Mean percent change from baseline to week 12 in the inflammatory (papules and pustules) lesion counts.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean percent change in non-inflammatory lesion counts.</measure>
    <time_frame>12 weeks</time_frame>
    <description>Mean percent change from baseline to week 12 in the non-inflammatory (open and closed comedones) lesion counts.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical response of &quot;success&quot;.</measure>
    <time_frame>12 weeks</time_frame>
    <description>The proportion of subjects at week 12 with a clinical response of &quot;success&quot; is defined as an Investigators Global Assessment score that is at least 2 grades less than the baseline assessment.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">1215</enrollment>
  <condition>Acne Vulgaris</condition>
  <arm_group>
    <arm_group_label>Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5% (Taro Pharmaceuticals Inc.)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Acanya® Gel, 1.2%/2.5%</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Acanya® (Clindamycin Phosphate and Benzoyl Peroxide) Gel, 1.2%/2.5% (Dow Pharmaceutical Sciences, Inc., marketed by Valeant Pharmaceuticals North America LLC)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle of test product</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Vehicle of test product (Taro Pharmaceuticals Inc.)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5%</intervention_name>
    <description>Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5% (Taro Pharmaceuticals Inc.)applied at approximately the same time once daily for 84 days (12 weeks).</description>
    <arm_group_label>Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5%</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acanya® Gel, 1.2%/2.5%</intervention_name>
    <description>Acanya® (Clindamycin Phosphate and Benzoyl Peroxide) Gel, 1.2%/2.5% (Dow Pharmaceutical Sciences, Inc., marketed by Valeant Pharmaceuticals North America LLC)applied at approximately the same time once daily for 84 days (12 weeks).</description>
    <arm_group_label>Acanya® Gel, 1.2%/2.5%</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vehicle of test product</intervention_name>
    <description>Vehicle of test product (Taro Pharmaceuticals Inc.)applied at approximately the same time once daily for 84 days (12 weeks).</description>
    <arm_group_label>Vehicle of test product</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Be willing and able to provide written informed consent/assent for the study.&#xD;
&#xD;
          -  Be 12 to 40 years of age, inclusive. A subject may be of either sex and any&#xD;
             race/ethnicity.&#xD;
&#xD;
          -  Have a clinical diagnosis of facial acne vulgaris with 25 or greater non-inflammatory&#xD;
             lesions and 20 or greater inflammatory lesions and no more than 2 nodulocystic&#xD;
             lesions.&#xD;
&#xD;
          -  Have a baseline Investigator's Global Assessment of acne severity grade of 2, 3 or 4&#xD;
             on a severity scale of 0 to 4.&#xD;
&#xD;
          -  Be willing and able to understand and comply with the requirements of the study, apply&#xD;
             the study medication as instructed, refrain from use of all other topical acne&#xD;
             medication and topical antibiotics during the 12-week treatment period, return for the&#xD;
             required treatment period visits, comply with therapy prohibitions, and able to&#xD;
             complete the study.&#xD;
&#xD;
          -  Be in general good health and free from any clinically significant disease, other than&#xD;
             acne vulgaris, that might interfere with the study evaluations.&#xD;
&#xD;
          -  Female subjects of childbearing potential must have a negative urine pregnancy test&#xD;
             amd must be willing to use a medically accepted method of contraception during the&#xD;
             study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Presence of more than 2 facial nodulocystic lesions (i.e., nodules and cysts).&#xD;
&#xD;
          -  Current diagnosis of acne conglobata, acne fulminans, or secondary acne.&#xD;
&#xD;
          -  Presence of active cystic acne, or polycystic ovarian syndrome.&#xD;
&#xD;
          -  History or presence of Crohn's disease, ulcerative colitis, regional enteritis, or&#xD;
             antibiotic-associated colitis.&#xD;
&#xD;
          -  Presence of any other facial skin condition that might interfere with acne vulgaris&#xD;
             diagnosis and/or assessment.&#xD;
&#xD;
          -  Excessive facial hair that would interfere with diagnosis or assessment of acne&#xD;
             vulgaris.&#xD;
&#xD;
          -  History of unresponsiveness to topical clindamycin phosphate and/or benzoyl peroxide&#xD;
             therapy.&#xD;
&#xD;
          -  Start or change of dose of estrogens or hormonal treatment 3 months prior to baseline&#xD;
             or throughout the study.&#xD;
&#xD;
          -  Use of medicated make-up throughout the study and significant change in the use of&#xD;
             consumer products within 30 days of study entry and throughout the study.&#xD;
&#xD;
          -  Use of any of the following treatments more recently than the indicated washout period&#xD;
             prior to visit 1/day 1; need or intent to continue to use any of the following&#xD;
             treatments during the study: oral retinoids or therapeutic Vitamin A supplements of&#xD;
             greater than 10,000 units/day; systemic steroids; systemic antibiotics; systemic&#xD;
             treatment for acne vulgaris ; systemic anti-inflammatory or immunosuppressive agents&#xD;
             (NSAID use is allowed on an as-needed basis but for no more than 7 days of consecutive&#xD;
             use, low dose aspirin is allowed if on a stable dose for at least 30 days);&#xD;
             Spironolactone; use on the face of cryodestruction or chemodestruction, dermabrasion,&#xD;
             photodynamic therapy, acne surgery, intralesional steroids, x-ray therapy; topical&#xD;
             retinoids; topical steroids; topical anti-acne medications; topical anti-inflammatory&#xD;
             agents; topical antibiotics; medicated cleansers; use of tanning booths, sun lamps,&#xD;
             sunbathing or excessive exposure to the sun; antipruritics, including antihistamines.&#xD;
&#xD;
          -  History of hypersensitivity or allergy to clindamycin phosphate, benzoyl peroxide, and&#xD;
             /or any ingredient in the study medication.&#xD;
&#xD;
          -  Females who are pregnant, breastfeeding, intending to become pregnant during the&#xD;
             study, or who do not agree to use an acceptable form of birth control during the&#xD;
             study.&#xD;
&#xD;
          -  Consumption of excessive alcohol, abuse of drugs, or a condition that could compromise&#xD;
             the subject's ability to comply with study requirements.&#xD;
&#xD;
          -  Any clinically significant condition or situation other than acne vulgaris that would&#xD;
             interfere with the study evaluations or optimal participation.&#xD;
&#xD;
          -  Use of any investigational drugs within 30 days prior to visit 1/day 1.&#xD;
&#xD;
          -  Participation in any other clinical study in the 30 days prior to signing the informed&#xD;
             consent form.&#xD;
&#xD;
          -  Previous participation in this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Symbio CRO</last_name>
    <role>Study Chair</role>
    <affiliation>http://symbioresearch.com/</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>May 2017</verification_date>
  <study_first_submitted>January 14, 2013</study_first_submitted>
  <study_first_submitted_qc>January 15, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 16, 2013</study_first_posted>
  <last_update_submitted>May 3, 2017</last_update_submitted>
  <last_update_submitted_qc>May 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acne Vulgaris</keyword>
  <keyword>Clindamycin Phosphate and Benzoyl Peroxide Gel</keyword>
  <keyword>Acanya® Gel</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acne Vulgaris</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clindamycin</mesh_term>
    <mesh_term>Clindamycin palmitate</mesh_term>
    <mesh_term>Clindamycin phosphate</mesh_term>
    <mesh_term>Benzoyl Peroxide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

